J. S. De Bono Et Al. , "PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations," Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) , vol.38, San-Francisco, Costa Rica, 2020
De Bono, J. S. Et Al. 2020. PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) , (San-Francisco, Costa Rica).
De Bono, J. S., Fizazi, K., Saad, F., Shore, N. D., Roubaud, G., Ozguroglu, M., ... Penel, N.(2020). PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations . Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica
De Bono, Johann Et Al. "PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations," Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica, 2020
De Bono, Johann S. Et Al. "PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations." Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) , San-Francisco, Costa Rica, 2020
De Bono, J. S. Et Al. (2020) . "PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations." Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) , San-Francisco, Costa Rica.
@conferencepaper{conferencepaper, author={Johann S. De Bono Et Al. }, title={PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations}, congress name={Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO)}, city={San-Francisco}, country={Costa Rica}, year={2020}}